Discussion
Treatment with Yorvipath (palopegteriparatide) was associated with early improvements in kidney function that were sustained for up to five years in adults with hypoparathyroidism, according to new data from two clinical trials. The pooled analysis of the Phase 2 PaTH Forward trial (NCT04009291) and the Phase…